SCHEMBL29664625

SCHEMBL29664625

N#Cc1ccccoc2cccnc2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 4/20 0.36
GAA P10253 3/20 0.36
MAPT P10636 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 4/20 0.35
RAB9A P51151 3/20 0.35
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP2A6 P11509 2/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
PSMB8 P28062 1/20 0.33
CTSK P43235 1/20 0.33
DAGLA Q9Y4D2 2/20 0.33
KCNMA1 Q12791 2/20 0.33
MAPK10 P53779 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664645 0.74 NPC1 (0.36) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL29664484 0.71 KDM4E (0.55) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL1994814 0.71 ALDH1A1 (0.47) KDM4EALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL29664499 0.70 SMN1; SMN2 (0.42) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL29533118 0.69 CYP2A6 (0.35) CYP2A6CTSK
Hydrochloric Acid SCHEMBL27619885 0.69 ALDH1A1 (0.46) KDM4EALDH1A1MAPTSMN1; SMN2MEN1
Benzofuran SCHEMBL23856124 0.66 KDM4E (0.41) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL2014239 0.65 GRM5 (0.45) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL148839 0.65
SCHEMBL29399634 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS FULCRUM THERAPEUTICS INC (US) 2024-07-18 US disclosed
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2023-02-28 US disclosed
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS BCLAF1, EED, BCL3 KDM4E 410/4885ALDH1A1 2107/4885GAA 3531/4885
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 KDM4E 88/4885ALDH1A1 1268/4885GAA 4287/4885
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators EED, EZH2, BMI1 KDM4E 88/4885ALDH1A1 1268/4885GAA 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.